Observing the safety of VYLOY in patients with gastric or GEJ cancer in South Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on individuals in South Korea diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer. Participants will receive VYLOY (zolbetuximab) as part of their standard treatment regimen, which is administered intravenously. The primary goal is to gather real-world data on the safety profile of VYLOY in this patient population, as well as to monitor the progression of their cancer over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who receive treatment with VYLOY injection, according to the approved local label.

Exclusion Criteria:

* Patients with any contraindication for VYLOY injection, according to the approved local label.
* Patients who are registered or scheduled to be registered in any clinical trials involving investigational drug administration.

Where it's running

• Site KR82010
  Goyang-si, Gyeonggi-do, South Korea Recruiting
• Site KR82008
  Suwon, Gyeonggi-do, South Korea Recruiting
• Site KR82009
  Suwon, Gyeonggi-do, South Korea Recruiting
• Site KR82014
  Uijeongbu-si, Gyeonggi-do, South Korea Recruiting
• Site KR82006
  Yangsan, Gyeongsangnam-do, South Korea Recruiting
• Site KR82012
  Hwasun Gun, Jeollanam-do, South Korea Recruiting

Study contacts

• Study coordinator: Astellas Pharma Global Development, Inc.
• Email: astellas.registration@astellas.com
• Phone: 800-888-7704

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zolbetuximab plus pembrolizumab and chemotherapy for stomach and gastroesophageal junction cancer

  This trial will test whether adding zolbetuximab to pembrolizumab and standard chemotherapy helps adults with Claudin 18.2-positive, HER2-negative locally advanced or metastatic stomach or gastroesophageal junction cancer.

  Recruiting at 187 sites Phase 3 Astellas Pharma Inc · Birmingham, Alabama and 252 other locations · NCT06901531

• Fruquintinib plus nab‑paclitaxel with iparomlimab and tuvonralimab for people with advanced gastric or GEJ cancer after immunotherapy

  This trial tests whether adding fruquintinib and two immune drugs (iparomlimab and tuvonralimab) to nab‑paclitaxel helps people with advanced gastric cancer whose disease progressed after first‑line immunotherapy.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07392346

• Lenvatinib with nivolumab and chemotherapy for metastatic gastric cancer with malignant ascites

  This trial tests whether adding lenvatinib to nivolumab plus chemotherapy helps people with metastatic gastric or gastroesophageal junction adenocarcinoma who have peritoneal metastases and significant malignant ascites.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07149090

• Zolbetuximab with paclitaxel and ramucirumab for CLDN18.2-positive stomach and gastro‑esophageal junction cancer

  This treatment tests whether adding zolbetuximab to paclitaxel and ramucirumab helps adults with metastatic gastro‑esophageal adenocarcinoma whose tumors are CLDN18.2‑positive live longer.

  Recruiting Phase 2 Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT06962137

• Testing BDC-4182 for advanced gastric and gastroesophageal cancer

  This study is testing a new drug called BDC-4182 to see if it's safe and how well it works for people with advanced gastric and gastroesophageal cancer.

  Recruiting at 16 sites Phase 1/2 Bolt Biotherapeutics, Inc. · Darlinghurst, New South Wales and 15 other locations · NCT06921837

• Investigating OKN4395 and Pembrolizumab for Solid Tumors

  This study is testing a new drug called OKN4395, alone and with another drug called pembrolizumab, to see if it can help people with solid tumors who have run out of other treatment options.

  Recruiting at 10 sites Phase 1 Epkin · Beverly Hills, California and 9 other locations · NCT06789172

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.